A 5-year re-rate is plausible if treated-patient throughput becomes repeatable and at least one in vivo program earns durable clinical credibility. The upside is real, but the binding constraints are care delivery, regulatory timing, and durability follow-up.

CASGEVY can move from “hero cases” to repeatable center throughput while in vivo liver editing earns clinical credibility; if CRSP productizes workflow + outcomes verification (and leverages owned GMP), it can re-rate from a single-asset profit share into a multi-asset gene-medicine operator by 2031.

AI cheapens discovery and trial operations, but regulated trust, manufacturing reliability, and care-workflow coordination stay scarce. CRSP’s approvals, GMP capability, and potential to own verification/registry rails are durable control points; the obsolescence risk is a better delivery/modality leapfrogging ex vivo workflows.

The 5-year setup is a transition from a partner-led, operationally gated launch to an underwritable multi-program platform. If CASGEVY initiations continue converting to infusions as centers industrialize the workflow, investors can start valuing CRSP on repeatable treated-patient economics rather than “science risk.” A second leg comes from in vivo liver editing: even one program with clean safety and durable biomarker efficacy can shift the company’s narrative from ex vivo logistics to scalable delivery, supporting a higher terminal multiple. Additive upside comes from owning workflow and outcomes verification rails that make CRSP harder to disintermediate in a world where cognition is cheap but regulated trust and auditability are scarce.

The binding risks are (1) care-delivery throughput (initiation→infusion conversion) rather than demand, (2) regulatory timing for pediatric expansion and future programs, (3) platform re-rating hinging on 2026–2027 in vivo data quality and durability, and (4) concentration on a partnered asset where CRSP does not fully control commercialization pace.

They sell regulated, high-trust therapies where the scarce asset is not “thinking,” but verified outcomes, compliance, and reliable delivery through specialized centers. AI helps them iterate faster, but scaling is constrained by real-world treatment logistics and any safety or durability surprises.

$82.91